Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Trastuzumab deruxtecan
AstraZeneca
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
1 trial -
Trodelvy 200 mg powder for concentrate for solution for infusion
Gilead Sciences Pty Limited
Metastatic Solid Tumors
1 trial -
Tumor Intiltrating Lymphocytes (TIL) – VHIO, Fludarabina Teva 25 mg/ml concentrado para solución para perfusión o inyección EFG, Melanoma Tumor Intiltrating Lymphocytes (TIL) – NKI, Fludarabine - PCH 25 mg/ml, concentraat voor oplossing voor intraveneuze infusie of injectie, ANV419, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Genoxal 1.000 mg polvo para solución inyectable y para perfusión, PROLEUKIN, 18x106 UI polvo para solución inyectable o para perfusión, PROLEUKIN®
The George Institute
Advanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.
1 trial -
VB10.NEO
Nektar Therapeutics UK Limited
Locally Advanced or Metastatic Solid Tumours
1 trial -
VESANOID 10 mg, capsule molle
The George Institute
Oligometastatic solid cancer
1 trial -
Valemetostat Tosylate, Valemetostat Tosylate
The George Institute
Adult patients with histologically/cytologically confirmed progressive metastatic or recurrent solid tumor, who have selected chromatin remodeling deficiency in at least one of the following genes: SMARCB1, SMARCA4, SMARCA2, SMARCC1, SMARCC2, ARID1A, ARID1B, PBRM1, BAP1and other SWI/SNF sub-units; or molecularly (Wildtype) and phenotypically-selected Clear cell endometrial or ovarian carcinoma cancers.
1 trial -
WTX-330
Werewolf Therapeutics
Advanced or Metastatic Solid Tumors
2 trials -
XTX202
Xilio Therapeutics
Advanced Solid Tumor
1 trial -
XTX301
Xilio Therapeutics
Advanced Solid Tumor
1 trial -
YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, KITE-363
Lacuna Pharma Pty Ltd
Solid and Hematological Malignancies
1 trial -
Zilovertamab vedotin
Merck Sharp and Dohme
Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults
1 trial -
Zirabev 25 mg/ml concentrate for solution for infusion, SAR445877, Erbitux 5 mg/mL solution for infusion, Zirabev 25 mg/ml concentrate for solution for infusion
Sanofi-aventis Healthcare Pty Ltd
Solid tumor
1 trial -
[177Lu]-NeoB solution for infusion, AAA503
Advanced Accelerator Applications
Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake.
1 trial -
anti-IL8 mAb, Ipilimumab, anti-IL8 mAb, 5% dextrose solution for injection, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, 0.9% sodium chloride solution for injection
Bristol-Myers Squibb Australia Pty Ltd
Advanced solid tumors
1 trial -
cemiplimab (monotherapy)
Regeneron UK Limited
Relapsed Solid Tumor
1 trial -
cetrelimab, JNJ-63723283
Janssen-Cilag International N.V.
Advanced Stage Solid Tumors
1 trial -
dabrafenib
GlaxoSmithKline
Solid Tumours
1 trial -
docetaxel+CDDP
Solid Biosciences
Head and Neck Squamous Cell Carcinoma
1 trial -
farletuzumab ecteribulin, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules
Eisai Co.,
Solid tumors in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer adenocarcinoma; NSCLC).
1 trial -
genexolPM + cisplatin
Solid Biosciences
Locally Advanced Head and Neck Squamous Cell Carcinoma
1 trial -
indibulin
Alaunos Therapeutics
Advanced Solid Tumors
2 trials -
ipatasertib
United Therapeutics Europe Ltd
Solid Tumor
1 trial -
ivosidenib and nivolumab
Agios Netherlands B.V.
Advanced Solid Tumor
1 trial -
rezatapopt
PMV Pharmaceuticals
Advanced Solid Tumor
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources